Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10365425" target="_blank" >RIV/00216208:11110/17:10365425 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/17:10365425

Result on the web

<a href="http://dx.doi.org/10.1007/s11096-017-0522-7" target="_blank" >http://dx.doi.org/10.1007/s11096-017-0522-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11096-017-0522-7" target="_blank" >10.1007/s11096-017-0522-7</a>

Result language

angličtina

Original language name

Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation

Original language description

Background: Although measurement of drug serum levels is an objective direct method for testing compliance, it can be distorted by &quot;white-coat compliance&quot; or by variations in drug elimination. Objective: The aim of this prospective study was to evaluate the prevalence of noncompliance with perindopril therapy in adult out-patients using pharmacokinetic simulations. The additional aim was to compare the predictive performance of two glomerular filtration rate markers-creatinine and cystatin C. Setting: Department of Cardiology, Tomas Bata Regional Hospital in Zlin, Czech Republic. Method: Perindoprilat pharmacokinetic models individualized according to patient characteristics were compared with measured perindoprilat serum concentrations to document compliance. Linear regression was used to evaluate the relations between perindoprilat clearance and glomerular filtration rate estimated using creatinine and cystatin C. Main outcome measure: Assessment of non-compliance with medication using drug concentration measurements reinforced with therapeutic drug monitoring. Results: Non-detectable perindoprilat levels were observed in 26.1% of patients. Another 21.7% were classified as non-compliant based on therapeutic drug monitoring pharmacokinetic simulations. Volume of distribution, clearance and half-life median value (interquartiA degrees range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h(-1) and 24.7 (19.4-62.7) h, respectively. Linear regression models showed tight relationship between cystatin C and perindoprilat clearance. Conclusions: Assessment of adherence with medication reinforced with therapeutic drug monitoring and pharmacokinetic simulations is proposed as an optimal method reducing disadvantages of simple drug concentration measurements. Cystatin C proves to be better surrogate marker for perindoprilat elimination than creatinine.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Clinical Pharmacy

ISSN

2210-7703

e-ISSN

—

Volume of the periodical

39

Issue of the periodical within the volume

5

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

6

Pages from-to

1095-1100

UT code for WoS article

000415360600017

EID of the result in the Scopus database

2-s2.0-85027016372